CD9 and carcinoma: Therapeutic monoclonal antibodies (mAbs) targeting different tetraspanin members including TSPAN8, CD9, CD37 and CD151 have been explored in preclinical models and clinical trials for the treatment of hematological malignancies and carcinomas [173,174,175,176,177].